摘要
目的:白细胞介素-6(IL-6)与脑胶质瘤的恶性增殖密切相关,本文探讨缓激肽作用大鼠C6胶质瘤细胞后对IL-6表达的影响。方法:应用逆转录聚合酶链反应(RT-PCR)和放射免疫法分别检测1μmol·L-1缓激肽作用下,C6胶质瘤细胞内及细胞培养液中IL-6的表达水平。结果:RT-PCR结果显示缓激肽作用于C6胶质瘤细胞,在不同时相点(0,5,10,15,30,60min)均有IL-6mRNA的表达,各组间比较无显著性差异(P>0.05);放射免疫法结果显示,细胞培养液中未检测到IL-6的表达。结论:缓激肽作用C6胶质瘤细胞60min以内不引起IL-6的表达增强,这为缓激肽临床应用的安全性提供了有利的实验依据。
Objective： To investigate the effect of bradykinin on the expression of interleukin-6 （IL-6） in C6 glioma cells. Methods： Semi-quantitative RT-PCR and radioimmunoassay were used to detect the expression of IL-6 mRNA in C6 glioma cells and IL-6 protein in culture medium from cells treated with 1μmol/L bradykinin, respectively. Results： Semi-quantitative RT-PCR revealed that IL-6 mRNA was detected at different time points （0, 5, 10, 15, 30 and 60 min） in C6 glioma cells after treatment with bradykinin at 1μmol/L, but there was no significant difference between the treatment group and the control group （P〉0.05）. Radioimmunoassay revealed that expression of IL-6 protein was not detected in the cell culture medium. Conclusion： There is a close correlation between interleukin- 6 （IL-6） expression and malignant proliferation in glioma. Bradykinin fails to evoke an enhancement in the expression of IL-6 in C6 glioma cells within an hour, which may provide a favorable experimental basis for the clinical application of bradykinin.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2007年第13期721-723,共3页
Chinese Journal of Clinical Oncology
基金
国家自然科学基金( 编号: 30670723
30600060
30400145
30570650)
辽宁省自然科学基金( 编号: 20052102)
高等学校博士学科点专项科研基金资助( 编号: 20050159005)
